Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- ILa | -.--% | -0.67% | -16.62% |
05-08 | Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-14 | Top Premarket Gainers | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 23/02/21 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 02/08/21 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 30/06/21 |
Roger Waltzman
CTO | Chief Tech/Sci/R&D Officer | 56 | 06/08/23 |
Walt Linscott
COO | Chief Operating Officer | 63 | 30/06/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 02/08/21 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 02/08/21 |
Robert Martell
BRD | Director/Board Member | 61 | 12/01/23 |
Hila Karah
BRD | Director/Board Member | 55 | 30/06/21 |
Michael Newman
FOU | Founder | 68 | 23/02/21 |
Roger Pomerantz
CHM | Chairman | 67 | 31/07/21 |
Director/Board Member | 71 | 30/06/21 | |
Mark Gilbert
BRD | Director/Board Member | 63 | 31/10/21 |
Company contact information
Sector
- Stock Market
- Equities
- INDP Stock
- NTEC Stock
- Company Intec Pharma Ltd